Madrigal Pharmaceuticals’ REZDIFFRA Shines as GLP-1 Drugs Approach the MASH Market

Madrigal Pharmaceuticals has recently captured significant attention in the race to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). As the landscape of liver disease therapeutics evolves,…

Continue Reading Madrigal Pharmaceuticals’ REZDIFFRA Shines as GLP-1 Drugs Approach the MASH Market

Beyond Reason

Patient Worthy is grateful to our partner Elephants & Tea for providing the following article by Laura DeKraker Lang-Ree, a cancer caregiver to her daughter Cecilia who survived childhood leukemia.…

Continue Reading Beyond Reason

Cure Rare Disease Expands Leadership Team to Accelerate Treatments for Ultra-Rare Conditions

Cure Rare Disease (CRD), a pioneering nonprofit biotechnology organization, has announced the addition of new scientific and strategic leaders, marking a significant step forward in its mission to develop therapies…

Continue Reading Cure Rare Disease Expands Leadership Team to Accelerate Treatments for Ultra-Rare Conditions

New European Project Aims to Improve Rare Disease Diagnosis and Care: Insights from the RARE-Impact Initiative

A recent article published in the Orphanet Journal of Rare Diseases highlights the launch and goals of RARE-Impact, a new European project designed to enhance the diagnosis, care, and overall…

Continue Reading New European Project Aims to Improve Rare Disease Diagnosis and Care: Insights from the RARE-Impact Initiative